| Name | Title | Contact Details |
|---|
Canadian International Pharmacy Association is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.
We help you connect patients and researchers to ensure data reliability, with proven solutions that simplify every step of the patient journey. Our deep therapeutic area expertise, agile technology and service scale enable us to minimize risk, innovate, and support your important work. We seek speed, efficiency and reduced variability to help you extend the reach of drug development, expand patient opportunities and improve data quality helping you bring life-changing therapies to our families and communities around the world.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.